Fms‐like tyrosine kinase 3 (FLT3) is a receptor tyrosine kinase that is a drug target for
leukemias. Several potent inhibitors of FLT3 exist, and bind to the inactive form of the …

FMS‐like tyrosine kinase 3 (FLT3) has been found to be mutated in~ 30% of acute myeloid
leukaemia patients. Small‐molecule inhibitors targeting FLT3 that are currently approved or …

Gilteritinib is a highly selective and effective inhibitor of the FLT3/ITD mutated protein, and is
used successfully in treating acute myeloid leukaemia (AML). Unfortunately, tumour cells …

Activating mutations in FMS-like tyrosine kinase 3 (FLT3) occur in 25% of acute lymphoid
and 30% of acute myeloid leukaemia cases. Therefore, FLT3 is a potential therapeutic target …

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in
the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor …

FMS-like tyrosine kinase 3 (FLT3) gene mutations have been found in more than one-third of
Acute Myeloid Leukemia (AML) cases. The most common point mutation in FLT3 occurs at …

FMS-like tyrosine kinase 3 (FLT3) is an attractive target for acute myeloid leukemia. Recent
studies have suggested that the application of small-molecule kinase inhibitors is a …

FMS-like tyrosine kinase 3 (FLT3) serves as an important drug target for acute myeloid
leukemia (AML), and gene mutations of FLT3 have been closely associated with AML …

Fms‐like tyrosine kinase 3 (FLT 3) belongs to the receptor tyrosine kinase family and
expressed in hematopoietic progenitor cells. FLT 3 gene mutations are reported in~ 30% of …

Tyrosine kinase domain mutations are a common cause of acquired clinical resistance to
tyrosine kinase inhibitors (TKI) used to treat cancer, including the FLT3 inhibitor quizartinib …